

02-28-05

Ifw/\$

PC25144A
Correction of Inventorship

Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 24th day of February 2005.

s/

Rachel Potash
Rachel Potash

EV496345593US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
SUZANNE BENEDICT, et al.

Group Art Unit: 1625

Serial No.: 10/754,171

Examiner: AULAKH, CHARANJIT

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN
KINASE INHIBITORS FOR ENHANCING THE
EFFICACY OF ANTI-NEOPLASTIC AGENTS
AND RADIATION THERAPY

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CORRECTION OF INVENTORSHIP IN AN APPLICATION

37 CFR 1.48 (a)

Applicant requests to correct the Inventorship in the above-referenced application pursuant to 37 CFR 1.48(a). Inventors Yong Wang and JinJiang Zhu were inadvertently omitted from the Application. This error occurred without deceptive intent.

As requested in 37 CFR 1.48(a), Applicant attaches the following documents:

1. A statement from each person being added as an inventor that the error in inventorship occurred without deceptive intention on his part;
2. An oath or declaration required by §1.67 (a)(2);
3. The processing fee set forth in §1.17(i); and
4. The written consent of the assignee set forth in §3.73(b).

If any other fees are due in connection with the filing of this response please charge all necessary fees to the deposit account 500329.

Respectfully submitted,

Date:

2/24/05

Reena R. Desai

Reena R. Desai
Agent For Applicants
Registration No. 53,833

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 526-4932 Fax: (858) 678-8233

10754171

500329

03/02/2005 H0000055

130.00 DA

01 FC:1464

PC25144A
Correction of Inventorship



Certificate of Mailing (37 C.F.R. §1.10):

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail (EV496345593US) in an envelope addressed to: Mail Stop: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this ~~23rd~~^{24th} day of February 2005.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
SUZANNE BENEDICT, et al .

Serial No.: 10/754,171

Filed: January 9, 2004

For: **TRICYCLIC COMPOUNDS PROTEIN
KINASE INHIBITORS FOR ENHANCING THE
EFFICACY OF ANTI-NEOPLASTIC AGENTS
AND RADIATION THERAPY**

Group Art Unit: 1625

Examiner: **AULAKH, CHARANJIT**

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF INVENTOR IN AN APPLICATION
37 CFR 1.48 (a)(2)

I, Yong Wang, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted,

Date: _____

2/22/2005

Yong Wang
Yong Wang



Effective on 12/08/2004.

Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL

For FY 2005

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 130.00

Complete if Known

Application Number	10/754,171
Filing Date	January 9, 2004
First Named Inventor	Suzanne Benedict
Examiner Name	Aulakh, Charanjit
Art Unit	1625
Attorney Docket No.	PC25144A

METHOD OF PAYMENT (check all that apply)☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify): _____☒ Deposit Account Deposit Account Number: 500329 Deposit Account Name: Agouron Pharmaceuticals,

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below☐ Charge fee(s) indicated below, except for the filing fee☒ Charge any additional fee(s) or underpayments of fee(s) under 37 CFR 1.16 and 1.17☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION**1. BASIC FILING, SEARCH, AND EXAMINATION FEES**

Application Type	FILING FEES		SEARCH FEES		EXAMINATION FEES		Fees Paid (\$)
	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	Fee (\$)	Small Entity Fee (\$)	
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	

2. EXCESS CLAIM FEESFee Description

Each claim over 20 (including Reissues)

Each independent claim over 3 (including Reissues)

Multiple dependent claims

Fee (\$)	Small Entity Fee (\$)
50	25
200	100
360	180
Multiple Dependent Claims	
Fee (\$)	Fee Paid (\$)

Total Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
--------------	--------------	----------	---------------

- 20 or HP = _____ x _____ = _____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims	Extra Claims	Fee (\$)	Fee Paid (\$)
---------------	--------------	----------	---------------

- 3 or HP = _____ x _____ = _____

HP = highest number of independent claims paid for, if greater than 3.

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof	Fee (\$)	Fee Paid (\$)
--------------	--------------	--	----------	---------------

- 100 = _____ / 50 = _____ (round up to a whole number) x _____ = _____

4. OTHER FEE(S)

Non-English Specification, \$130 fee (no small entity discount)

Fees Paid (\$)
130.00

Other (e.g., late filing surcharge): Correction of Inventorship**SUBMITTED BY**

Signature	<u>Reena R. Desai</u>	Registration No. (Attorney/Agent)	53,833	Telephone	858-526-4932
Name (Print/Type)	Reena R. Desai	Date	<u>2/24/05</u>		

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PC25144A
Correction of Inventorship



Certificate of Mailing (37 C.F.R. §1.10):
I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail (EV496345593US) in an envelope
addressed to: Commissioner for Patents, PO Box 1450,
Alexandria, VA 22313-1450
on this ^{23rd}~~24th~~ day of February 2005.

s/ Rachel Potash
Rachel Potash

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
SUZANNE BENEDICT, et al.

Serial No.: 10/754,171

Filed: January 9, 2004

For: TRICYCLIC COMPOUNDS PROTEIN
KINASE INHIBITORS FOR ENHANCING THE
EFFICACY OF ANTI-NEOPLASTIC AGENTS
AND RADIATION THERAPY

Group Art Unit: 1625

Examiner: AULAKH, CHARANJIT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450


STATEMENT OF INVENTOR IN AN APPLICATION
37 CFR 1.48 (a)(2)

I, Jinjiang Zhu, was inadvertently omitted as an inventor in United States Patent Application No. 10/754,171, filed January 9, 2004. This error in inventorship occurred without deceptive intention on my part.

Respectfully submitted,

Date: 2/22/05

Jinjiang Zhu
Jinjiang Zhu

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: Agouron Pharmaceuticals, Inc.Application No./Patent No.: 10/754,171 Filed/Issue Date: 01/09/2004Entitled: Tricyclic Compounds Protein Kinase Inhibitors For Enhancing The Efficacy Of Anti-Neoplastic Agents And Radiation TherapyAgouron Pharmaceuticals, Inc., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

A ☒ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel 014358, Frame 0202, or for which a copy thereof is attached.

OR

B ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

February 16, 2005

Signature

Date

Bryan C. Zielinski858-622-8864

Printed or Typed Name

Telephone Number

Assistant Secretary

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, (and Preliminary Amendment, if applicable), or
- ☒ Application No. 10/754,171, filed on January 9, 2004
- ☒ as amended on January 13, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

Full Name of Inventor(s)

Inventor 1 SUZANNE BENEDICT

Signature *Suzanne Benedict* Citizen of US

Inventor 2 MICHAEL BENNETT

Signature *Michael Bennett* Citizen of US

Inventor 3 SACHA NINKOVIC

Signature *Sacha Ninkovic* Citizen of CANADA

Inventor 4 MIN TENG

Signature *Min Teng* Citizen of US

☒ Additional inventors are being named on page 2

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

**DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)**

As the below named inventor(s), I/we declare that:

This declaration is directed to:

- ☐ The attached application, (and Preliminary Amendment, if applicable), or,
- ☒ Application No. 10,754,171, filed on January 9, 2004
- ☒ as amended on January 13, 2005 (if applicable);

I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;

I/we have reviewed and understand the contents of the above-identified application, including the claims, as amended by any amendment specifically referred to above;

I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.

All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.

Full Name of inventor(s)

Inventor 5 EUGENE RUI

Signature

Citizen of US

Inventor 6 FEN WANG

Signature

Citizen of CHINA

Inventor 7 YONG WANG

Signature

Citizen of US

Inventor 8 JINJIANG ZHU

Signature

Citizen of CANADA

☐ Additional inventors are being named on

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 CFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.